Encouragingly, although hormone receptor positive breast cancer appears to be the least immunogenic type of breast cancer34, we have shown that imiquimod can induce a robust anti-tumor immune response leading to clinical response in the three patients with hormone receptor positive disease described here. Here, NR4A1 is linked to neoplasm.